Form 8-K Humacyte, Inc. For: Mar 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/11/2026
- Wall St set to gain on tech rebound, Middle East in focus
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil rises as Trump repeats Iran attack threat
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Alibaba falls on China AI capex report; Citi says selloff is premature
- Crude Inventory Fell 7.2 Million Barrels Last Week, Says EIA
Humacyte suspends $60 million stock offering program
March 19, 2026 8:28 AM EDTHumacyte Inc. (NASDAQ: HUMA) terminated its at-the-market equity offering program on March 19, 2026, according to a company statement.
The biotechnology company delivered written notice to TD Securities (USA) LLC, which served as the sales agent, suspending the prospectus dated December 16, 2025. The prospectus... More
